Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Distribution of KRAS and BRAF Mutations in Metastatic Colorectal Cancers in Turkish Patients

  • Gorukmez, Orhan (Medical Genetics Unit, Sevket Yilmaz Training and Research Hospital) ;
  • Yakut, Tahsin (Department of Medical Genetics, School of Medicine, Uludag University) ;
  • Gorukmez, Ozlem (Department of Medical Genetics, School of Medicine, Uludag University) ;
  • Sag, Sebnem Ozemri (Department of Medical Genetics, School of Medicine, Uludag University) ;
  • Karkucak, Mutlu (Medical Genetics Unit, Sakarya Training and Research Hospital) ;
  • Kanat, Ozkan (Department of Medical Oncology, School of Medicine, Uludag University)
  • Published : 2016.04.11
Download PDF
⟨ Previous Next ⟩

Abstract

The results of this study demonstrate the potential prognostic and predictive values of KRAS and BRAF gene mutations in patients with colorectal cancer (CRC). It has been proven that KRAS and BRAF mutations are predictive biomarkers for resistance to anti-EGFR monoclonal antibody treatment in patients with metastatic CRC (mCRC). We demonstrated the distribution of KRAS (codons 12, 13 and 61) and BRAF (codon 600) gene mutations in 50 mCRCs using direct sequencing and compared the results with clinicopathological data. KRAS and BRAF mutations were identified in 15 (30%) and 1 (2%) patients, respectively. We identified KRAS mutations in codon 12, 13 and 61 in 73.3% (11/15), 20% (3/15) and 6.67% (1/15) of the positive patients, respectively. The KRAS mutation frequency was significantly higher in tumors located in the ascending colon (p=0.043). Thus, we found that approximately 1/3 of the patients with mCRC had KRAS mutations and the only clinicopathological factor related to this mutation was tumor location. Future studies with larger patient groups should yield more accurate data regarding the molecular mechanism of CRC and the association between KRAS and BRAF mutations and clinicopathological features.

Keywords

References

  1. Benedix F, Kube R, Meyer F, et al (2010). Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Diseases Colon Rectum, 53, 57-64. https://doi.org/10.1007/DCR.0b013e3181c703a4
  2. Brand T, Wheeler D (2012). KRAS mutant colorectal tumors: past and present. Small GTPases, 3, 34-9. https://doi.org/10.4161/sgtp.18751
  3. Brenner H, Kloor M, Pox C (2014). Colorectal cancer. Lancet, 383, 1490-502. https://doi.org/10.1016/S0140-6736(13)61649-9
  4. Bufill J (1990). Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Internal Med, 113, 779-88. https://doi.org/10.7326/0003-4819-113-10-779
  5. Chang Y, Chang S, Yeh K, et al (2013). RAS, BRAF, and TP53 gene mutations in Taiwanese colorectal cancer patients. Onkologie, 36, 719-24.
  6. Ciardiello F, Tortora G (2008) Drug therapy: EGFR antagonists in cancer treatment. New Engl J Med, 358, 1160-74. https://doi.org/10.1056/NEJMra0707704
  7. Cunningham D, Humblet Y, Siena S, et al (2004). Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. New Engl J Med, 351, 337-45. https://doi.org/10.1056/NEJMoa033025
  8. Di Nicolantonio F, Martini M, Molinari F, et al (2008). Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol, 26, 5705-12. https://doi.org/10.1200/JCO.2008.18.0786
  9. Ferreira C, Aran V, Zalcberg-Renault I, et al (2014). KRAS mutations: variable incidences in a Brazilian cohort of 8,234 metastatic colorectal cancer patients. Bmc Gastroenterol, 14.
  10. Friday B, Adjei A (2008). Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res, 14, 342-46. https://doi.org/10.1158/1078-0432.CCR-07-4790
  11. Iacopetta B (2002). Are there two sides to colorectal cancer? Int J Cancer, 101, 403-8. https://doi.org/10.1002/ijc.10635
  12. Jean G, Shah S (2008). Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer. Pharmacotherapy, 28, 742-54. https://doi.org/10.1592/phco.28.6.742
  13. Lin J, Chang S, Wang H, et al (2006). Distinctive clinicopathological features of Ki-ras mutated colorectal cancers. J Surgical Oncol, 94, 234-41. https://doi.org/10.1002/jso.20438
  14. Marchoudi N, Joutei H, Jouali F, et al (2013). Distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer. Pathologie Biologie, 61, 273-6. https://doi.org/10.1016/j.patbio.2013.05.004
  15. Ozen F, Ozdemir S, Zemheri E, et al (2013). The proto-oncogene kras and braf profiles and some clinical characteristics in colorectal cancer in the turkish population. Genetic Testing Molecular Biomarkers, 17, 135-9. https://doi.org/10.1089/gtmb.2012.0290
  16. Pai R, Jayachandran P, Koong A, et al (2012). BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. American J Surgical Pathol, 36, 744-52. https://doi.org/10.1097/PAS.0b013e31824430d7
  17. Patel G, Karapetis C (2013). Personalized treatment for advanced colorectal cancer: KRAS and beyond. Cancer Manage Res, 21, 387-400.
  18. Roberts P, Der C (2007). Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene, 26, 3291-310. https://doi.org/10.1038/sj.onc.1210422
  19. Rosty C, Young J, Walsh M, et al (2013). Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features. Modern Pathol, 26, 825-34. https://doi.org/10.1038/modpathol.2012.240
  20. Samowitz W, Curtin K, Schaffer D, et al (2000). Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: A population-based study. Cancer Epidemiol Biomarkers Prev, 9, 1193-7.
  21. Shen Y, Wang J, Han X, et al (2013). Effectors of epidermal growth factor receptor pathway: the genetic profiling of KRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine. Plos One, 8.
  22. Soong R, Powell B, Elsaleh H, et al (2000). Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma: influence of tumour site, stage, adjuvant chemotherapy and type of mutation. Eur J Cancer, 36, 2053-60. https://doi.org/10.1016/S0959-8049(00)00285-9
  23. Sugai T, Habano W, Jiao Y, et al (2006). Analysis of molecular alterations in left- and right-sided colorectal carcinomas reveals distinct pathways of carcinogenesis - Proposal for new molecular profile of colorectal carcinomas. J Molecular Diagnostics, 8, 193-201. https://doi.org/10.2353/jmoldx.2006.050052
  24. Tong J, Lung R, Sin F, et al (2014). Characterization of rare transforming KRAS mutations in sporadic colorectal cancer. Cancer Biology Therapy, 15, 768-76. https://doi.org/10.4161/cbt.28550
  25. Venook A (2005), Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma. Cancer, 103, 2435-46. https://doi.org/10.1002/cncr.21123
  26. Yokota T (2012). Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers? Anti-Cancer Agents in Medicinal Chemistry, 12, 163-71. https://doi.org/10.2174/187152012799014968
  27. Yokota T, Ura T, Shibata N, et al (2011). BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. British J Cancer, 104, 856-62. https://doi.org/10.1038/bjc.2011.19
  28. Zlobec I, Bihl M, Schwarb H, et al (2010). Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis. Int J Cancer, 127, 367-80.